Revive Therapeutics $RVVTF

Amazing Sales of Paxlovid (CBS News).

"These medicines have a sweet spot. If the day you get diagnosed COVID you say 'forget it, I'll be fine,' and then...
Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...
Roland Rick Perry

Tax Loss Selling Bargain? Adding Aditxt (ADTX).

Adding Aditxt (ADTX) to the upcoming "2022 Biotech 6-Pack, Stocks We Expect to Double" Watch List.

The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...

The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21. Revive Therapeutics (RVTTF), RedHill BioPharma...

Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Not wanting to be caught...

Mitesco (MITI) Sets Opening Dates for New Minneapolis Clinics, Additional Sites in Minneapolis and...

MINNEAPOLIS, MN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Mitesco, Inc. (OTCQB:MITI) ("Mitesco" or the "Company"), a leading operator of wellness clinics...
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE

Aphex BioCleanse (SNST) Making Serious Headlines.

Relatively quiet for most of the year. Aphex BioCleanse, our favorite Super Bug sanitizer company, made two back-to-back announcements - signaling things...
Issam Radd

Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary

Latest article

ARK VS. SARK | PAST STANCES

Long Ark Innovation 10/3/2022 | $37.90 #ARK, #ARKK, #SARK

ARK vs. SARK

Ever get really, really bearish and really, really wish you could find a simple way to make money in a bear market?

Adding ‘Internet of Things,’ Direct Communications (DCSX) $1.17 to the Watch List.

Chris Bursey, Member of Verizon's Internet of Things (IOT) Advisory Council, Charges Ahead as CEO of Direct Communication (DCSX).